Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

#160; Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.  The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.   Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. 

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually.  Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release.  For instance, any statements in this press release concerning prospe
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  Victoria Vein & Surgery Clinic is ... Astanza Duality laser in Victoria, Texas . ... well as advanced laser treatments for a variety of medical ... industry to provide more services for their patients. Since adding ... Victoria residents get rid of their ...
(Date:3/27/2015)... 27, 2015 A new report from Kalorama Information ... – Chile , Colombia ... targets for IVD firms.  The healthcare research firm said that ... strategies for the Latin American continent with a population of ... supply operations. However, the country,s regional economic clout does not ...
(Date:3/27/2015)... March 27, 2015 XRpro Sciences, Inc., ... discovery and development services which features high throughput ... industry, announced financial results for the year ended ...  Tyson, Chairman of XRpro Sciences commented, "We have ... from development stage to commercial stage in large ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... , SAN DIEGO, Dec. 21 ... their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, ... The first trial in human subjects, NBI-98854-0801, was a ... in Canada under an approved Clinical Trial Application (CTA) ...
... , CARLSBAD, Calif., Dec. 21 Isis Pharmaceuticals, Inc. ... a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: ... OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 ... that has completed a successful Phase 2 program in patients ...
Cached Medicine Technology:Neurocrine Advances VMAT2 Inhibitor Program 2Neurocrine Advances VMAT2 Inhibitor Program 3Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:3/28/2015)... 2015 Coffee could not only perk you ... from gum disease, researchers have found. , They found that ... Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, then, ... Boston Univ. Henry M. Goldman School of Dental Medicine explored ... issue of the Journal of Periodontology. , “This is the ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... game with knights, nature, and peasants. , The ... to Eurogamer. The popularity of these games grew over ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared ... UniWigs during the Easter Holidays from today until April ... April Fools’ Day. , As the winter fades and ... Easter Festival, with religious origins to countries in Europe ... Christmas. The best wig provider, UniWigs, would like to ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... estimated 15,000 - 20,000,members, ATLANTA, Dec. 4 ... week, to accommodate its growing membership in,DeKalb County ... ceremony for the new Stonecrest Medical Center was ... Ramsey, Georgia State,Representative Stan Watson, DeKalb County Commissioner ...
... The National,Organization of Life & Health Insurance Guaranty ... associations that are playing,a central role in the ... Company of New York (ELNY) matter., NOLHGA ... the ELNY situation: "NOLHGA and all of our ...
... antibiotics and nasal steroids don,t lessen symptoms , , TUESDAY, ... work no better than a placebo in combating sinus ... probably not as effective as have been previously believed, ... said study author Dr. Ian Williamson, a senior lecturer ...
... BMIs experience a significant survival benefit from liver ... transplant compared to patients with normal BMI. Therefore, ... listed for transplantation, say the authors of a ... a journal by John Wiley & Sons. The ...
... and heart,s electrical system , , TUESDAY, Dec. 4 (HealthDay ... spotted patients at highest risk of cardiac arrest or ... researchers report. , "This is important because past studies, ... people at risk," said study lead author Dr. Derek ...
... M.D., Chair of,Neurosurgery at Yale University School of ... American Epilepsy Society (AES), during the,organization,s 61st annual ... physicians and scientists who study and treat epilepsy., ... surgical treatment of,neurological diseases causing epilepsy. He developed ...
Cached Medicine News:Health News:Kaiser Permanente Opens 15th Medical Facility in Georgia 2Health News:Statement on Executive Life of New York Matter 2Health News:Sinusitis Treatments Found Ineffective 2Health News:Sinusitis Treatments Found Ineffective 3Health News:Liver transplant offers survival benefits for patients of all sizes 2Health News:Liver transplant offers survival benefits for patients of all sizes 3Health News:2-in-1 Test Signals Risk After Heart Attack 2Health News:2-in-1 Test Signals Risk After Heart Attack 3
These backbiters enable simple access to the anterior horn of the meniscus....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: